Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement
An erratum to this article was published (Eur J Endocrinol, 30 May 2025 ↗)
Methodological details4 rounds of voting, 18 international experts from 11 countries, consensus ≥75% agreement, Consensus defined as ≥75% agreement
- 4 rounds of voting
- 18 international experts from 11 countries
- Consensus ≥75% agreement
- Consensus defined as ≥75% agreement
Recommendations
As issued by the authors
Thromboprophylaxis should be considered at Cushing's syndrome (CS) diagnosis and continued for 3 months after biochemical remission, provided there are no obvious contraindications
Standard weight-based prophylactic dose of low molecular-weight heparin is the preferred agent for thromboprophylaxis in CS
Perioperatively and around inferior petrosal sinus sampling, thromboprophylaxis should be reconsidered if not already initiated at diagnosis
For venous thromboembolism (VTE) treatment, extended thromboprophylaxis is advised, continuing for 3 months after Cushing is resolved
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →